BR112021011289A2 - Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo - Google Patents

Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo

Info

Publication number
BR112021011289A2
BR112021011289A2 BR112021011289A BR112021011289A BR112021011289A2 BR 112021011289 A2 BR112021011289 A2 BR 112021011289A2 BR 112021011289 A BR112021011289 A BR 112021011289A BR 112021011289 A BR112021011289 A BR 112021011289A BR 112021011289 A2 BR112021011289 A2 BR 112021011289A2
Authority
BR
Brazil
Prior art keywords
cancer
active ingredient
weissella cibaria
prevention
treatment
Prior art date
Application number
BR112021011289A
Other languages
English (en)
Inventor
Hak Jong Choi
Mi Sun Yun
Original Assignee
Korea Food Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Food Res Inst filed Critical Korea Food Res Inst
Publication of BR112021011289A2 publication Critical patent/BR112021011289A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo. se refere a uma nova weissella cibaria wikim28 (no de acesso kccm11879p) isolada de kimchi e uma composição compreendendo a mesma como um ingrediente ativo. a weissella cibaria wikim28 de acordo com a presente invenção apresenta excelente atividade anticancerígena em modelos animais nos quais uma célula cancerígena é transplantada, e, portanto, pode ser proveitosamente usada como uma composição em uso no tratamento, prevenção ou melhora de câncer de humanos ou animais.
BR112021011289A 2018-12-10 2019-11-29 Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo BR112021011289A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180158672A KR102009742B1 (ko) 2018-12-10 2018-12-10 와이셀라 시바리아 wikim28을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
PCT/KR2019/016747 WO2020122484A1 (ko) 2018-12-10 2019-11-29 와이셀라 시바리아 wikim28을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
BR112021011289A2 true BR112021011289A2 (pt) 2022-04-26

Family

ID=67624750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021011289A BR112021011289A2 (pt) 2018-12-10 2019-11-29 Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo

Country Status (10)

Country Link
US (1) US20220031774A1 (pt)
EP (1) EP3895717A4 (pt)
JP (1) JP7282891B2 (pt)
KR (1) KR102009742B1 (pt)
CN (1) CN113164528A (pt)
AU (1) AU2019396103B2 (pt)
BR (1) BR112021011289A2 (pt)
CA (1) CA3122291A1 (pt)
SG (1) SG11202106160WA (pt)
WO (1) WO2020122484A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022020865A2 (pt) 2020-01-31 2022-11-29 Liscure Biosciences Co Ltd Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
KR102339314B1 (ko) 2020-01-31 2021-12-14 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 wikim28을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022145900A1 (ko) * 2020-12-28 2022-07-07 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20220094153A (ko) 2020-12-28 2022-07-05 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 균주 유래 나노소포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20220118225A (ko) * 2021-02-18 2022-08-25 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
KR20220120503A (ko) 2021-02-22 2022-08-30 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20220120502A (ko) 2021-02-22 2022-08-30 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 lbml2 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022177411A1 (ko) * 2021-02-22 2022-08-25 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 lbml2 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022177412A1 (ko) * 2021-02-22 2022-08-25 주식회사 리스큐어바이오사이언시스 와이셀라 시바리아 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102390755B1 (ko) 2021-09-06 2022-04-28 한국식품연구원 웨이셀라 파라메센테로이데스 WiKim0137 균주를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
CN113930367B (zh) * 2021-11-12 2023-11-14 安琪生物科技有限公司 一株具有降胆固醇性能的乳酸菌及其应用
CN115300522A (zh) * 2022-08-09 2022-11-08 郑州大学第一附属医院 食窦魏斯氏菌d-2胞外多糖在抑制人结肠癌细胞中的应用
CN117229980B (zh) * 2023-11-08 2024-01-30 北京市农林科学院 一种食窦魏斯氏菌发酵饲料及其应用与除臭效果

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101014317B1 (ko) * 2008-12-24 2011-02-14 한국식품연구원 건강기능활성을 가지는 와이셀라 시바리아 148-2 균주 및 이를 포함하는 막걸리
KR101287120B1 (ko) 2011-10-28 2013-07-17 대상에프앤에프 주식회사 락토바실러스 플란타륨 ｄｓｒ ｃｋ10또는 락토바실러스 플란타륨 ｄｓｒ ｍ2를 유효성분으로 함유하는 암 치료용 조성물
KR20150068061A (ko) 2013-12-11 2015-06-19 부산대학교 산학협력단 항암활성이 우수한 기능성 김치 및 그 제조방법
KR20160023457A (ko) * 2014-08-22 2016-03-03 주식회사 대유위니아 김치 숙성방법
KR101667496B1 (ko) * 2015-10-15 2016-10-18 한국식품연구원 김치 유산균 와이셀라 시바리아(Weissella cibaria) WIKIM28을 유효성분으로 포함하는 아토피 피부염 치료용 약학 조성물
KR101834383B1 (ko) * 2016-11-14 2018-03-05 한국식품연구원 항비만 활성을 갖는 와이셀라 시바리아 WIKIM28(Weissella cibaria WIKIM28) 및 이를 포함하는 조성물
KR20180054029A (ko) * 2016-11-14 2018-05-24 전북대학교산학협력단 웨이셀라 시바리아로부터 유래한 세포외 다당류를 포함하는 면역력 증강을 위한 조성물

Also Published As

Publication number Publication date
JP2022511893A (ja) 2022-02-01
CN113164528A (zh) 2021-07-23
WO2020122484A1 (ko) 2020-06-18
EP3895717A4 (en) 2022-11-23
CA3122291A1 (en) 2020-06-18
EP3895717A1 (en) 2021-10-20
SG11202106160WA (en) 2021-07-29
KR102009742B1 (ko) 2019-08-12
JP7282891B2 (ja) 2023-05-29
AU2019396103B2 (en) 2023-04-13
AU2019396103A1 (en) 2021-07-22
US20220031774A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
BR112021011289A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MD3500564T2 (ro) Inhibitori ai diacilglicerol aciltransferazei 2
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
BR112013027609A2 (pt) bactérias bacillus para uso no tratamento e prevenção de infecção em animais aquáticos
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
BR112017014740A2 (pt) composto espiro tricíclico
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
UY36274A (es) Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
BR112021011293A2 (pt) Composição farmacêutica para prevenção ou tratamento de câncer compreendendo lactobacillus sakei wikim30 como ingrediente ativo
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
MX2020008275A (es) Metodos para tratar trastornos mitocondriales.
EA201890188A1 (ru) Новый бициклический липолантипептид, его получение и применение в качестве противомикробного средства
BR112017016278A2 (pt) agente preventivo e/ou terapêutico de doença imune
BR112019022459A2 (pt) Agente terapêutico para câncer no sangue

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]